U. S. Department of Health and Human Services
U. S. Food and Drug Administration
Center for Food Safety and Applied Nutrition
Office of Plant & Dairy Foods & Beverages
December 4-5, 2002


Food Advisory Committee
Contaminants and Natural Toxicants
Subcommittee Meeting

Toxicology Component of FDA's Action Plan for Acrylamide

December 4-5, 2002

Begin Presentation


Author: Richard Canady, PhD DABT


Table of Contents
  1. Toxicology Component of FDA's Action Plan for Acrylamide
  2. Goal of the toxicity component of FDA's action plan
  3. Context for toxicology research
  4. Data gap evaluations
  5. Outline of presentation of what we know, need, and are planning
  6. 1. What we know for toxicokinetics
  7. 1. Toxicokinetics data needs
  8. 1. Plans for Toxicokinetics data development
  9. 2. What we know for cancer
  10. 2. Carcinogenicity data needs
  11. 2. FDA carcinogenicity study plans: intermediate to long term
  12. 2 . FDA carcinogenicity study plans shorter term
  1. 3. Neurotoxicity
  2. 3. Neurotoxicity data needs
  3. 3. Plans for neurotoxicity study
  4. 4. Reproductive/ developmental effects (other than neurotoxicity)
  5. 4. Reproductive/ developmental effects data needs
  6. 4. Plans for Reproductive/ developmental effects study
  7. 5. Safety/risk assessment USEPA RfD and USFDA ADI
  8. 5. WHO/FAO Safety/risk assessment
  9. WHO/FAO conclusion
  10. Safety/risk assessment - Effective dose, Exposure, ADI
  11. Summary


Presentations at Acrylamide Public Meeting

Download presentation source (PPT format)

Acrylamide in Foods
Foods Home   |   FDA Home   |   HHS Home   |   Search/Subject Index   |   Disclaimers & Privacy Policy   |   Accessibility/Help

Hypertext updated by las/bpd/cjm 2002-DEC-30